Vectus Biosystems

Vectus Biosystems Debt Growth

The Year-over-Year Debt Growth of Vectus Biosystems (VBS.AX) as of Nov 5, 2026 is 173.33 %. In the previous year, Year-over-Year Debt Growth was 591.42 % — a change of -70.69% (lower).

Debt Growth

173.33 %

YoY

-70.69%

Last updated:

Year-over-Year Debt Growth of Vectus Biosystems is 2026 173.33 % . Year-over-Year Debt Growth of Vectus Biosystems was 2025 591.42 % . It decreases by -70.69% lower compared to the previous year.

The Vectus Biosystems Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2019
115.56 AUD
Jan 1, 2020
321.27 AUD
Jan 1, 2021
4.83 AUD
Jan 1, 2022
-20.49 AUD
Jan 1, 2023
-98.98 AUD
Jan 1, 2024
-58.80 AUD
Jan 1, 2025
591.42 AUD
Jan 1, 2026
173.33 AUD
The Vectus Biosystems Debt Growth history
YEARDebt GrowthYoY
173.33 %-70.69%
591.42 %-1,105.81%
-58.80 %-40.60%
-98.98 %+383.19%
-20.49 %-524.05%
4.83 %-98.50%
321.27 %+178.03%
115.56 %-55.30%
258.51 %-94.82%
4,987.70 %-71,062.57%
-7.03 %-92.06%
-88.56 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Vectus Biosystems Stock analysis

What does Vectus Biosystems do? Vectus Biosystems Ltd. generates revenue through the development and commercialization of pharmaceutical products targeting fibrotic diseases and hypertension. The company focuses on VB0004, a compound designed to treat tissue hardening and high blood pressure, alongside candidates for fibrotic liver conditions like NASH and pulmonary fibrosis. Its subsidiary Accugen Pty Limited offers the Accugen platform, which provides qPCR reagents and software for accurate DNA and RNA quantification in laboratory testing. The primary buyers of these products are pharmaceutical companies and research institutions seeking advanced drug development tools and therapies for fibrotic disorders. Vectus Biosystems targets the medical research and development sector, specifically addressing unmet needs in fibrotic disease treatment. The Accugen platform serves laboratories requiring efficient molecular analysis tools, with its technology enhancing the speed and precision of qPCR testing. The company’s revenue streams are derived from both therapeutic product development and the sale of diagnostic solutions to biotech firms and academic research entities. The firm’s focus on fibrosis-related treatments, including heart, kidney, and liver diseases, positions it within niche therapeutic segments. Accugen’s reagents and software are sold to laboratories as part of the qPCR workflow, supporting drug discovery processes. Pharmaceutical companies and research organizations are the key segments purchasing Vectus Biosystems’ products for their R&D pipelines and clinical applications. Vectus Biosystems is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectus Biosystems stock

Year-over-Year Debt Growth of Vectus Biosystems is 173.33 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth Vectus Biosystems since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's Vectus Biosystems historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Vectus Biosystems

All Key Metrics — Vectus Biosystems